{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:51:32Z","timestamp":1781589092836,"version":"3.54.5"},"reference-count":17,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2026,6]]},"abstract":"ABSTRACT<\/jats:title>\n \n Purpose<\/jats:title>\n \n Spontaneous reporting of a possible link between myelin oligodendrocyte glycoprotein (\n MOG<\/jats:styled-content>\n ) antibody\u2010associated disease (\n MOGAD<\/jats:styled-content>\n ) and\n mRNA SARS<\/jats:styled-content>\n \u2010\n CoV<\/jats:styled-content>\n \u20102 vaccination warrants further examination. Hence, the objective of this study was to investigate the association between\n MOG<\/jats:styled-content>\n \u2010\n IgG<\/jats:styled-content>\n positivity as a proxy for\n MOGAD<\/jats:styled-content>\n and\n mRNA SARS<\/jats:styled-content>\n \u2010\n CoV<\/jats:styled-content>\n \u20102 vaccination in the Danish population.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We applied the self\u2010controlled case series study using Danish nationwide health registers. The study population consisted of all Danish residents who were offered an\n mRNA COVID<\/jats:styled-content>\n \u201019 vaccination and had a first positive\n MOG<\/jats:styled-content>\n \u2010\n IgG<\/jats:styled-content>\n test result between November 1, 2020 to December 31, 2023.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 5.9 million individuals eligible for\n SARS<\/jats:styled-content>\n \u2010\n CoV<\/jats:styled-content>\n \u20102 vaccination, we identified 111 incident events of\n MOG<\/jats:styled-content>\n \u2010\n IgG<\/jats:styled-content>\n positivity in the study period of which 28 (25%) occurred in children. We found no association between\n mRNA SARS<\/jats:styled-content>\n \u2010\n CoV<\/jats:styled-content>\n \u20102 vaccination and\n MOG<\/jats:styled-content>\n \u2010\n IgG<\/jats:styled-content>\n positivity in adults, but an increased risk\u2014although based on small numbers\u2014was found in children below 18\u2009years of age (incidence rate ratio\u2009=\u20098.07, 95% confidence intervals: 3.07\u201321.21). If the observed association reflects a causal effect, the estimated number of excess\n MOG<\/jats:styled-content>\n \u2010\n IgG<\/jats:styled-content>\n positive events attributable to\n mRNA COVID<\/jats:styled-content>\n \u201019 vaccination in Denmark was 4.38 per 1\u2009000\u2009000 exposed children.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n These results suggest an increased risk of\n MOG<\/jats:styled-content>\n \u2010\n IgG<\/jats:styled-content>\n positivity after\n mRNA SARS<\/jats:styled-content>\n \u2010\n CoV<\/jats:styled-content>\n \u20102 vaccination in children, but not in adults. The number of additional\n MOGAD<\/jats:styled-content>\n events attributable to\n mRNA SARS<\/jats:styled-content>\n \u2010\n CoV<\/jats:styled-content>\n \u20102 vaccination in children is very low and further studies are needed to confirm these findings.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/pds.70403","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:08:25Z","timestamp":1780272505000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Association Between\n MOG<\/scp>\n \u2010\n IgG<\/scp>\n Positivity and\n mRNA SARS<\/scp>\n \u2010\n CoV<\/scp>\n \u20102 Vaccination in Denmark: A Self\u2010Controlled Case Series Study"],"prefix":"10.1002","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3729-4420","authenticated-orcid":false,"given":"Tine Iskov","family":"Kopp","sequence":"first","affiliation":[{"name":"Data Analytics Centre, Danish Medicines Agency Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Katrine","family":"Andreasen","sequence":"additional","affiliation":[{"name":"Regulatory & Clinical Assessment, Danish Medicines Agency Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Papp","sequence":"additional","affiliation":[{"name":"Department of Neurology, Danish Multiple Sclerosis Center Copenhagen University Hospital\u2014Rigshospitalet Glostrup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7072-0933","authenticated-orcid":false,"given":"Mette Hjorslev","family":"Knudgaard","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance Danish Medicines Agency Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi Jeannet","family":"Graff","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance Danish Medicines Agency Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Clement","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance Danish Medicines Agency Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicklas Hasselblad","family":"Lundstr\u00f8m","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance Danish Medicines Agency Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine","family":"Uls\u00f8","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance Danish Medicines Agency Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona El\u2010Sayed","family":"Hervig","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance Danish Medicines Agency Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Wessel","family":"Skovlund","sequence":"additional","affiliation":[{"name":"Data Analytics Centre, Danish Medicines Agency Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,31]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8709-21"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11194-9"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103693"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25909"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519845112"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.201800019"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.01.100"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9325"},{"key":"e_1_2_10_11_1","volume-title":"Modern Epidemiology","author":"Rothman K. J.","year":"2008"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2022.12.015"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200063"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231154780"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2018-104"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103739"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281972"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000366"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70403","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.70403","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:52:13Z","timestamp":1781585533000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/pds.70403"],"URL":"https:\/\/doi.org\/10.1002\/pds.70403","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,31]]},"assertion":[{"value":"2026-01-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70403"}}